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Introduction
Tuberculosis (TB) has recently regained attention
in the international infectious disease news with
the emergence of disease caused by highly drug-
resistant strains of Mycobacterium tuberculosis in
South Africa and the former Soviet Union. This
highly resistant form of disease is called exten-
sively drug resistant TB or "XDR TB" and is
caused by isolates that have developed not only
resistance to isoniazid and rifampin, but also to a
fluoroquinolone and at least one of three injectable
second-line drugs (i.e., amikacin, kanamycin, or
capreomycin).1
The spread of TB and XDR TB is fueled by poor
access to TB care, crowding, and the HIV epi-
demic.2 In the former Soviet Union, a weakened
public health system has contributed to the emer-
gence and spread of resistant TB - especially in
prison settings. The epidemics of injection drugs
and TB have converged in Soviet prisons, a prob-
lem that is compounded by frequent interruptions
of TB medication supply and antiquated approach-
es to care.3
While XDR TB is still not common (of 17,690 M.
tuberculosis isolates obtained world-wide in 2003-
2004, 20% were from patients with multidrug
resistant (MDR) TB [i.e., resistant to isoniazid and
rifampicin] and 2% were from patients with XDR
TB) 1, the emergence of XDR TB in prison settings
in the former Soviet Union, and the spread of XDR
to the outside communities to which inmates and
correctional officers belong, illustrates once again
the important role that front-line professionals
such as correctional health providers have to play
in protecting the health of their charges and com-
munities. This issue of IDCR will address a matter
of perennial concern: TB treatment and prevention
in correctional facilities.
XDR and MDR TB Prevalence
The emergence of resistance to anti-TB drugs is a
phenomenon that occurs primarily due to poor TB
control and inadequate management of TB dis-
ease. Problems include incorrect drug prescribing
practices by providers, poor quality or erratic sup-
ply of drugs, and patient non-adherence. 
XDR TB has been identified in all regions of the
world but is most frequent in the countries of the
former Soviet Union and in Asia. In the United
States, 4% of MDR TB cases met the criteria for
XDR TB. In Latvia, a country with one of the high-
est rates of MDR TB, 19% of MDR TB cases met
the XDR TB criteria. Separate data on a recent
outbreak of XDR TB in a population of HIV-infect-
ed patients in Kwazulu-Natal in South Africa was
characterized by high mortality rates and deaths
occurring within days to weeks after diagnosis. An
investigation of this outbreak found that of the 544
TB patients studied, 221 had MDR TB; 47 out of
the 544 patients and six health care workers were
found to have XDR TB. Of the 53 subjects with
XDR TB, 44 were found to have HIV infection, and
52 died, on average, within 25 days of XDR TB
diagnosis, including those who were being treated
with and responding to antiretroviral therapy.4 
TB in the U.S.
In 2006, the prevalence of TB in the U.S. was 4.6
per 100,000 population.  Although the TB case
rates are much lower in the U.S. than rates else-
where in the world, the rate of decline in TB preva-
lence has slowed in recent years, in part due to
the persistence of TB among foreign-born popula-
tions and delayed diagnosis and treatment among
members of racial and ethnic minority groups.
Rates among American blacks, Asians and
Hispanics were 8.4, 21.2, and 7.6 times higher
than rates among whites, respectively. 5  The high-
est statewide TB case rate was 12.6 per 100,000,
in Washington DC, (which is reported as a state in
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IDCR and AAHIVM have united to improve
the quality of health care delivery in the
nation's correctional facilities by leveraging
the knowledge, experience and resources of
two diverse and accomplished groups of HIV
and correctional health care experts. 
TB IN CORRECTIONS: CONSTANT COMPANION AND FUTURE SCOURGE
Box 1. Definitions of MDR and XDR TB
MDR TB, or multidrug-resistant TB, is a spe-
cific form of drug-resistant TB. It occurs when
the TB bacteria are resistant to at least isoni-
azid and rifampicin, two first line TB drugs. 
XDR TB, or extensively drug-resistant TB is
caused by an organism that in addition to
being resistant to isoniazid and rifampin
(MDR) also has resistance to any fluoro-
quinolone and at least one of three injectable
second-line drugs (capreomycin, kanamycin,
and amikacin).  
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Dear Correctional Colleagues,
As long as there have been humans, there has been tuberculosis.  For millennia Mycobacterium
tuberculosis has been shortening lives and today continues to ravage.  Over a third of the popu-
lation of our planet harbors the bacterium and an increasing subset is infected with drug resistant
strains.  
As with many of today's major infectious disease threats, human behavior has played a major role
in fostering crisis. Indiscriminate use of anti-tuberculosis medications, suboptimal treatment
adherence, cuts in the funding of successful tuberculosis (TB) control programs, global migration
and the concentrating of persons at risk for the infection in medical and correctional facilities have
each contributed to the resurgence in this infection; added to these is the companion epidemic of
HIV.
Together these factors conspire within prisons and jails to create a 'perfect storm' in which the
organism can be efficiently transmitted.  Therefore, it is essential that correctional systems take
seriously the threat posed by TB and implement policies and procedures to screen, diagnosis and
treat those with the disease while limiting opportunities for the spread of the infection.  Effective
TB control programming requires knowledge, diligence and funding.  We at IDCR cannot help with
the last two but have dedicated this issue to the first in order to help increase understanding of TB
for those working within jails and prisons.
IDCR Editor in Chief, Dr. Anne DeGroot and Dr. Renee Ridzon of the Bill and Melinda Gates
Foundation have co-authored a comprehensive review of the major issues in the management
and control of TB in correctional settings.  A pair of case studies from Drs. Edward Gardner and
Robert Belknap from Denver Public Health accompanies their article.  
As we confront a world where multiple drug resistant TB is a frightening reality, it is essential we
in corrections, of all people, not be lax when it comes to TB.  The consequence of our failure would
be dire and can be summed up vividly in one word: Russia.  
David A. Wohl, MD
Associate Professor of Medicine
Division of Infectious Diseases
AIDS Clinical Research Unit 
The University of North Carolina - Chapel Hill
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terms of U.S. TB surveillance). Seven 
states (CA, FL, GA, IL, NJ, NY and TX) report-
ed more than 500 cases each - these states
account for 60% of all TB cases.5 (See Figure
1).
TB in U.S. Correctional Systems
While TB is on the decline in the U.S. and
MDR TB rates are stable and low, both TB
disease and latent TB infection (LTBI) are rel-
atively prevalent inside U.S. prisons and jails.
Reported TB case rates in federal and state
prisons in 2003 were 29.4 and 24.2 cases per
100,000 inmates, respectively. These rates
are considerably higher than the TB case
rates reported for the non-inmate population
in the U.S. reported for the same year (5.1 per
100,000 people).6 The incidence of new
cases of TB is also higher among inmates
than non-incarcerated populations. In 1994 in
New Jersey, the incidence of TB was 91.2
cases per 100,000 inmates, compared to a
rate of 11.0 cases per 100,000 persons
among all New Jersey residents.  In  1991, a
TB case rate for inmates of a California prison
was 184 cases per 100,000 persons, which
was 10 times greater than the statewide rate.
In 2005, 16.5% and 10.5% of all reported TB
cases in AZ and TX, respectively were in per-
sons who were residents of correctional facil-
ities.7 
An investigation of TB cases in Memphis
County demonstrates the significant role that
correctional facilities play in the transmission
and potential control of TB. This study exam-
ined the history of incarceration in all TB
cases in the county and found that 43% of the
TB cases reported in 1995 through 1997 were
in persons who had previous contact with the
jail. This suggests that the jail may have
played an important part in contributing to the
transmission of M. tuberculosis in the com-
munity as well as provided a potential location
for prevention efforts in those who eventually
developed cases of TB.9
Latent TB in correctional settings
The prevalence of LTBI seen among U.S.
inmates can be as high as 25%. 10 A correla-
tion has also been demonstrated between
length of incarceration and positive tuberculin
skin test (TST) response, indicating that trans-
mission of M. tuberculosis is not uncommon in
correctional facilities.10 For this reason, jail
and prison inmates, correctional officers and
correctional health professionals are consid-
ered a "high risk group" that would benefit 
from annual TST screening, the best means to
determine if there has been recent transmis-
sion of M. tuberculosis within a correctional
facility (See Diagnostic Tests for TB, below).
Outbreaks in correctional settings
At least three factors contribute to the high
rate of TB in correctional and detention facili-
ties. First, incarceration leads to the concen-
tration of individuals at high risk for TB (e.g.,
users of injected drugs, persons of low socio-
economic status, and persons with HIV infec-
tion) and who are unlikely to have received TB
screening or treatment prior to incarceration.
Second, crowded living conditions facilitate
transmission. Third, the movement of inmates
(without their medical records) from institution
to institution, makes implementation of TB
control measures difficult. 
Reports of outbreaks of TB within U.S. pris-
ons and jails are published on an almost
annual basis.11-17 In most of these outbreaks,
epidemiology and strain typing verified trans-
mission of a single strain of M. tuberculosis.
Some of these outbreaks involved MDR
strains; in several of these outbreaks, trans-
mission occurred not only among inmates, but
also to health care staff within the correction-
al facilities, and to members of the communi-
ties to which inmates were released. Several
outbreaks that have been recently reported
are summarized below:
Florida, 2001-2004. This outbreak of TB
described in the February 2005 issue of IDCR
illustrates the need for periodic screening of
correctional staff members.18 The outbreak
investigation uncovered five cases of TB
among correctional staff members that
occurred over a period of two and a half years
(May 2001-September 2004). The source
case was an HIV-infected correctional staff
member who was non-adherent with TB treat-
ment. Restriction fragment length polymor-
phism, which is used to distinguish among
strains of M. tuberculosis demonstrated that
four of the five cases were caused by an iden-
tical strain, indicating a probable common
source. Although mandatory screening and
testing of all employees had been implement-
ed three years prior to this outbreak, correc-
tional staff members often did not comply.
Additional prison-associated outbreaks have
occurred in other regions of Florida; investi-
gation of these outbreaks is ongoing.
Kansas, 2002. In Kansas, a single inmate
with infectious TB had contact with more than
800 individuals as he was transferred from
one jail (jail A) to two others (jails B and C)
and eventually was remanded to a state
prison. There was a lapse of 11 months
between onset of symptoms and diagnosis. A
contact investigation identified 318 of the pos-
sible 800 contacts; two were diagnosed with
TB disease. Both were cellmates of the
source case, one in jail A and the other in jail
C. Isolates from all three patients had an iden-
tical-band RFLP.  Of the 318 contacts, six with
a prior documented negative skin test had a
positive skin test and of 196 with no prior skin
test information, 41 (21%) had a positive skin
test.19
South Carolina, 1999-2000. Segregating
HIV-infected prisoners in a South Carolina
prison contributed to a TB outbreak in which
71% of prisoners residing in the same hous-
ing area as the source case either had new
tuberculin skin test conversion or developed
TB disease. Thirty-one prisoners and one
medical student in the community's hospital
subsequently developed TB disease.15
Control of TB in Correctional Facilities
Control of TB in correctional facilities hinges
on several important measures. First and
most important is the rapid detection and
proper treatment of potentially infectious
cases of TB among inmates and staff. This is
best accomplished with a proper index of sus-
picion for signs and symptoms of TB disease
as well as adequate treatment and isolation of
those with potentially infectious disease so
that transmission of infection to others is min-
imized. Second is the prompt initiation of a
contact investigation with case finding for
additional cases of disease and those with
recently acquired infection so that treatment
can be administered. Third is initial and peri-
odic screening (where indicated) so that those
with undetected LTBI can be identified and
treatment of infection can be initiated and
completed, averting future cases of TB. 
All suspect TB cases and clusters of new
infections should be reported to the local TB
control program and treatment of infection
and disease should be conducted by those
with experience in the management of TB or
in consultation of those experienced in the
management of TB. Health care providers
with experience in the treatment of TB should
manage all cases of infection and disease
caused by drug resistant strains of M. tuber-
culosis. Apart from outbreaks of MDR TB in
the U.S. in the late 1980s and early 1990s
drug resistant TB in correctional facilities has
not been a significant problem.20,21This has
not been the case for the correctional sys-
tems of the former Soviet Union where a sig-
nificant number of cases of drug resistant TB,
including MDR TB have been and continue to
be seen. To date the outbreak of XDR TB in
South Africa is not known to involve prisoners,
but the possibility exists for introduction to
correctional facilities where, as has been
shown in many circumstances, transmission
may be enhanced. Because TB remains a
problem in correctional facilities, the Centers
for Disease Control and Prevention (CDC)
has recently issued updated guidelines for the
control of TB in these settings.22 This latest
set of guidelines focuses on case finding of
persons (including inmates and staff) with
potentially infectious pulmonary TB so that
diagnosis and treatment (if indicated) can be
promptly initiated to limit transmission of M.
tuberculosis in the facility. The guideline out-
lines methods and timing that should be used
to promptly screen inmates for TB disease in
order to limit transmission within the facility.
Recommendations for periodic screening are
based both on the risk in individual inmates
for TB and the risk of the facility as a whole.
Below are some highlights from the CDC's
2006 Prevention and Control of Tuberculosis
in Correctional and Detention Facilities guide-
lines (see reference for details on the recom-
mendations outlined below).
Diagnostic Tests for TB
TST. The TST administered by injecting puri-
fied protein derivative (PPD) by the Mantoux
method remains the most commonly used
tool for the detection of infection with M.
3
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Source: CDC. Trends in Tuberculosis Incidence
United States, 2006. MMWR 2007;56(11):245-50
RFLP - restriction fragment-length polymor-
phism pattern- a molecular pattern that dis-
tinguishes one strain of TB from another. 
Figure 1. Rate* of tuberculosis cases, by state -
United States. 2006  | *Per 100,000 population
0.0-3.5
3.6-4.6
4.7-7.0
> 7.1
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tuberculosis. In some persons with LTBI,
reaction to tuberculin may wane over years.  
When these persons are skin tested years
after infection, they may have a negative
reaction.  However, the skin test may stimu-
late (or "boost") their ability to react to tuber-
culin, resulting in a positive reaction to a sub-
sequent test.  With serial testing, the boosted
reaction may be misinterpreted as a newly
acquired infection. Two-step testing is used to
establish a reliable baseline TST status and
reduce the likelihood that a boosted reaction
will be misinterpreted as a recent infection
because the second step of testing uncovers
boosting. According to the updated guide-
lines, two-step testing should be used for ini-
tial testing in any individual (including staff
and inmates) who has not had a TST in the
prior 12 months. It should not need to be used
for periodic testing unless there is a lapse of
greater than 12 months between periodic
tests and should never be used in the context
of a contact investigation. The two-step test is
performed by placing an initial TST, and if that
test result is negative, then a second step
TST should be done one to three weeks later.
A positive reaction to the second-step test of
the two-step test probably represents a boost-
ed reaction. Although a boosted reaction
should not be considered a TST conversion, it
does indicate that that an evaluation for TB
disease should be undertaken and if TB is not
present, treatment for LTBI should be recom-
mended if indicated.
A more accurate test? 
In May 2005, the U.S. Food and Drug
Administration licensed QuantiFERON®-TB
Gold. (QFT-G). This in vitro test measures the
amount of cytokine (interferon-gamma) pro-
duced by cells in whole blood that have been
stimulated by peptides present in M. tubercu-
losis but absent from all BCG strains and from
the majority of commonly encountered non-
TB mycobacteria. The guideline outlines how
this new test can be used for screening in cor-
rectional settings and points out that the test
can be used as a diagnostic tool for M. tuber-
culosis infection, including both TB disease
and LTBI.  The utility of this test and the TST
in those with advanced HIV disease and oth-
ers with severe immunosuppression may be
limited because of false negative test results
and the use of QFT-G in the context of HIV
infection is an area where continued research
is needed. A negative TST or QFT-G in per-
sons with severe immunosuppression should
not be used as evidence to exclude the diag-
nosis of TB if there is presence of a reason-
able index of suspicion of TB or signs and
symptoms consistent with disease. 
Neither the QFT-G nor the TST can distin-
guish between LTBI and TB disease; both
tests must be used in conjunction with risk
assessment, clinical history and examination,
radiography, and other diagnostic evalua-
tions. Limitations of QFT-G include that a
blood specimen must be collected and
processed within 12 hours of collection, that
only a limited number of laboratories process
the test, and that there is a lack of clinical
experience in interpreting test results.
Advantages of the test include fewer false
positive tests from reactions from prior BCG
or infection with environmental mycobacteria
and elimination of the second visit for reading
the TST. The elimination of a second visit will
likely render the QFT-G competitive for a
screening tool. 
These new guidelines call for a classification
of correctional settings by risk of TB among
inmates, and how TB screening should be
conducted is dependent on the classification
of the facility as a minimal risk or non-minimal
risk facility. A facility is classified as minimal
risk if it meets all the following criteria:
No cases of infectious TB have occurred in
the facility in the last year;
The facility does not house substantial nu-
mbers of inmates with risk factors for TB
(e.g., HIV infection and injection drug use);
The facility does not house substantial
numbers of new  immigrants (i.e., persons
arriving in the U.S. within the previous five
(years) from areas of the world with high
rates of TB;
Employees of the facility are not otherwise
at risk for TB.
If these criteria are met, the facility should be
classified as minimal risk. If not, it should be
classified as non-minimal risk. 
Regardless of type of facility, symptom
screening for TB disease (including prolonged
cough, weight loss, fever, night sweats)
should be performed immediately on entry to
a facility. Inmates who have symptoms sug-
gestive of TB should be placed in an airborne
infection isolation room and promptly evaluat-
ed for TB disease.  If the facility does not have
an airborne infection isolation room and there
is a high suspicion of TB, the inmate should
be transferred to a facility where he/she can
be properly isolated so that a diagnostic eval-
uation can be conducted.23 
For inmates in minimal risk facilities who have
no symptoms of TB disease, only those with
risk factors for LTBI or who are at increased
risk of progressing from infection to disease
should be screened within seven days of
arrival with chest radiography or a TST or
QFT-G. Risk factors that should trigger
screening are shown in Box 2:
Regardless of the TST or QFT-G result,
inmates with known or suspected HIV infec-
tion or other severe immunosuppression
should have a chest radiograph taken as part
of the initial screening.
For those who are housed in non-minimal risk
facilities, all inmates without symptoms
should be screened with a TST, QFT-G
(where available), or a chest radiograph
should be performed within 7 days of arrival.
HIV-infected inmates, those suspected of
having HIV or those with immunocompromis-
ing conditions should have a chest radiograph
regardless of TST or QFT-G result as part of
the initial screening. The index of suspicion
for TB in those with HIV infection should be
very high as the presentation and radiograph-
ic appearance of TB in persons with
advanced immunosuppression can be atypi-
cal. 
Persons who have a positive TST or QFT-G
result should be further evaluated for TB dis-
ease with a chest radiograph and symptom
screen. The number of individuals who can
effectively be screened in jail setting is limited
because of the high rate of turnover and short
lengths of stay.
In addition to screening for TB disease and for
LTBI at entry, screening for LTBI should take
place annually thereafter with either the TST
or QFT-G in non-minimal risk settings and in
those in minimal risk settings. 
Protection of Staff
A medical history relating to TB should be
obtained and recorded for all new employees
upon hire, and a physical examination should
be required. In addition, TST or QFT-G
screening should be mandatory for employ-
ment. An annual TST or QFT-G should be
performed for all employees with negative
TST or QFT-G test. 
Treatment
LTBI. The preferred treatment for LTBI is nine
months of daily isoniazid or biweekly dosing
administered by directly observed therapy
(DOT). Individuals who have received BCG
vaccine are still considered to have LTBI if
their TST is positive (> 10mm). (See Table 1)
TB disease. In Spring 2003, the American
Thoracic Society Infectious Diseases Society
of America (IDSA), and the CDC issued
updated guidelines for the treatment of TB.1
These guidelines are substantially longer and
significantly more comprehensive than the
prior guidelines and should be referred to
when treating a patient with TB disease or
LTBI.  The guidelines provide a complete dis-
cussion of the drugs currently available to
treat TB, including dosing, dose adjustments
needed for renal or hepatic dysfunction, toxic-
ities, management of common adverse
effects and information about interactions
between antituberculosis drugs and other
Continued on page 5
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Box 2: Risk factors that should trigger
screening for TB disease
HIV infection (or suspicion of HIV
infection)
Recent immigration
History of TB
Recent close contact with a person
with TB disease
Injection-drug use
Diabetes mellitus
Immunosuppressive therapy
Hematologic malignancy or lymphoma
Chronic renal failure
Medical conditions associated with
substantial weight loss or malnutrition
History of gastrectomy or jejunoileal
bypass
Box 3. Diagnosis and treatment of LTBI 
CDC Recommendations: 
Regardless of age, correctional facility staff
and inmates in the following high-risk
groups should be given treatment for LTBI
if their reaction to the TST is >5 mm or is
the QFT-G is positive:
HIV-infected persons
Recent contacts of a TB patient
Persons with fibrotic changes on chest
radiograph consistent with previous TB 
disease
Patients with organ transplants and
other immuno-compromising cond-
tions who receive the equivalent of
>15 mg/day of prednisone for >1 month
Other inmates and staff
All other correctional facility staff and
inmates should be considered for treat-
ment of LTBI if their TST result is >10 mm
induration or if the QFT-G is positive
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drugs. Because rifamycins have the potential
for drug-drug interactions, including some
antiretroviral medications, there is special
attention given to the treatment of the patient
with co-infection with HIV and M. tuberculosis
(See TB 101). There is discussion of treat-
ment issues in special groups such as chil-
dren and pregnant and breast-feeding
women. Treatment completion is now deter-
mined by the number of doses delivered as
well as the duration of therapy. Also included
is an algorithm on how to manage treatment
interruption, a problem that is not uncommon
in correctional settings.
TB disease and LTBI should be treated by a
provider experienced in the management of
TB, or in consultation with an experienced
clinician. All cases of suspected or confirmed
TB disease should be promptly reported to
the local TB control program and a contact
investigation should be promptly initiated, if
indicated. Cure of TB disease and successful
treatment of infection depends on completion
of the recommended course of therapy. Since
the primary determinant of treatment outcome
is adherence to the regimen, DOT is the pre-
ferred treatment strategy. DOT should be
used throughout the entire course of therapy.
In the case of intermittent treatment regimens
for LTBI, nonadherence to dosing results in a
larger proportion of total doses missed than
daily dosing; therefore, all patients on inter-
mittent treatment should also receive DOT.
DOT should also be used with daily dosing of
LTBI treatment whenever feasible.
Practitioners providing treatment to inmates
should coordinate DOT with the local health
department on an inmate's release. 
DOT implementation in corrections can
require a rigorous approach. The first order of
business is the crafting of reliable
inmate/patient logs, which may be paper or
electronic. These should generate daily list-
ings of all DOT inmate/patients to receive
medication that day. In concert with security,
recall systems are required in order to track
down and bring to the clinic all "No-Shows" for
receipt of DOT. This may entail tracking down
not only voluntary "No-Shows", but also the
few cases that be unavailable to receive med-
icine, such as detainees/inmates who may
have been in court that day, or were tem-
porarily absent for a variety of reasons.
Finally, with inmates waiting for DOT security
cooperation in the form of a Deputy or correc-
tional officer will be needed. Once medication
is administered, there should be assurance
that it has been swallowed. This can be done
by shining a flashlight into the inmate/patient's
throat after medication is given. On the inside
of prison walls, as is also often true on the
outside, patients are likely to be more adher-
ent if they are well educated about their dis-
ease. 
Conclusions
Correctional facilities are not closed institu-
tions and are a part of the surrounding com-
munity.  Good public health practices inside
will lead to improved public health outside.
Movement between the facility and the com-
munity occurs through the arrival and depar-
ture of inmates, staff and visitors. Because of
this movement, poor TB control within correc-
tional facilities will eventually result in prob-
lems with TB control outside of these facilities.
Conversely, good TB control practices within
correctional facilities will translate to better TB
control within correctional facilities as well as
the surrounding communities. Correctional
facilities house and congregate members of
vulnerable populations who are at high risk for
TB. While this creates a situation where unde-
tected TB can spread easily, it also presents
an opportunity to provide interventions for
detecting and treating TB disease and LTBI
among a high risk population, resulting in an
overall benefit to the inmates and society and
a means to strive toward the goal of TB elim-
ination in the U.S.
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Table 1. Drug Regimens for the Treatment of LTBI
Drugs
Isoniazid
Isoniazid
Rifampin
Rifampin/Pyrazinamide
Duration (mo)
9
6
4
Generally should not be offered for
treatment of LTBI*
Interval
Daily
Twice Weekly
Daily
Twice Weekly
Daily
Minimum # Doses
270 doses
76 doses
180 doses
52 doses
120 doses
Source: CDC. Treatment of Latent Tuberculosis Infection. 2006:2. 
* CDC. Update: Adverse Event Data and Revised American Thoracic Society |CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent
Tuberculosis Infection. MMWR | 2003; 52 (No.31). http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5231a4.htm
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Case 1: 
A 28 year-old male was brought to a jail med-
ical facility after being arrested for assault. He
was intoxicated and complained of chest
pain, cough, and night sweats intermittently
for several weeks prompting the Sheriff's
Deputy to alert the facility nurse. He had no
significant past medical history, was born in
Mexico and had been living in the United
States for the past three years.  His vital signs
and physical exam were normal except for a
heart rate of 120 beats per minute.  A chest
radiograph showed a faint left upper lobe
fibronodular opacity. Based on his presenta-
tion the patient was placed in respiratory iso-
lation. What should you do next?
Discussion:
Diagnosing tuberculosis (TB) is challenging
because the symptoms are often nonspecific
and varied. The critical first step involves con-
sidering TB in the differential diagnosis for a
broad range of symptoms.  Approximately
half of all TB cases admitted to the hospital
have a delay in diagnosis primarily because
TB is not initially considered.1,2
The next step is to evaluate the patient's risk
factors for 1) latent TB infection and 2) TB
disease.  In the U.S., the most common risk
factor for infection is birth or residence in a
high prevalence country (essentially any-
where other than North America, Western
Europe, Australia or New Zealand).  Other
risks for infection include work or residence in
a correctional facility, nursing home, or other
congregate setting, current or prior home-
lessness, and substance abuse.  Common
risks for progression to TB disease include
HIV-infection, other immunosuppressive ill-
nesses or medications, diabetes, chronic
renal failure, and scarring from prior TB on
chest radiograph. 
All suspect patients should have a chest radi-
ograph performed.  Remember that the chest
radiograph cannot always differentiate
between active TB and old scarring.  Once
TB is suspected, the patient should be placed
in respiratory isolation until it is determined if
the patient has infectious pulmonary TB or an
alternative diagnosis is made.  All suspected
or confirmed TB cases should be promptly
reported to the department of health. In cor-
rectional settings without availability of air-
borne infection isolation rooms, evaluation of
suspect cases may require hospital admis-
sion.
Along with the chest radiograph, assessment
for active TB involves collecting three sputum
smears and cultures, and placing a tuberculin
skin test (TST) or performing a quantiferon
test.  These screening tools are helpful when
positive by confirming that the patient was
infected with M. tuberculosis at some time in
their life.  Alone the TST or quantiferon test
cannot distinguish between TB disease and
latent TB infection.  Both of these tests can
produce false negative results in as many as
25% of people with TB disease.3
Sputum smears and cultures are an impor-
tant part of an initial evaluation for pulmonary
TB.  Traditionally, sputum samples have been
collected on three successive mornings but
some have suggested samples collected 8
hours apart with at least one early morning
specimen may be adequate and shorten the
time needed to collect these diagnostic tests.
4,5 Unfortunately, sputum smears have a
poor sensitivity with only 50% of patients with
pulmonary TB having a positive smear.3
While smear positive TB patients are the
most infectious, patients who have smear
negative pulmonary disease can also trans-
mit M. tuberculosis.6 All suspect cases need
to be followed closely while waiting for culture
results and if released from incarceration,
should be referred to the local health depart-
ment for appropriate follow up.
In this case, the patient had a negative TST
and three negative sputum smears.  He was
discharged from the hospital on azithromycin
and released on bail. Three weeks later, cul-
tures of all three sputum specimens were
positive.  His only contact information turned
out to be a center for alcohol treatment where
he hadn't been since his arrest.  This high-
lights the importance of collecting extensive
contact information from patients, such as
this one, who had suspected TB.  Information
about family members and friends who may
know where the patient is located can be
obtained from the patient prior to release.  In
addition, reporting the suspected case to the
local department of health, in accordance
with local procedures, can be an important
element in post-release follow-up. This
patient was finally found a month later when
he returned to the treatment center and
learned the TB clinic was looking for him.  He
had an HIV antibody test performed and this
was negative.
He was started on four-drug TB therapy until
drug sensitivities were able to be completed.
A repeat TST while on treatment was strong-
ly positive which is not uncommon.  Two
months later his organism was found to be
sensitive to isoniazid and rifampin, his
remaining treatment was simplified to these
antibiotics, and he was continued on directly
observed therapy.
Case 2: 
A 29 year-old Hispanic male was referred to
the hospital from the state prison with post-
prandial abdominal pain for several months
that had acutely worsened over the past
week and was associated with nausea, vom-
iting and fevers.  He was born in Honduras,
had lived in the U.S. for 10 years and had
been incarcerated for six months.  An ultra-
sound showed a thickened gall bladder and
dilated extra-hepatic biliary ducts. He was
diagnosed with cholecystitis and initially
treated with intravenous levofloxacin and
metronidazole.  He improved clinically and
was discharged to the prison infirmary on
intravenous ticarcillin/clavulanate, but
returned to the hospital three days later for
increasing pain and fevers.  What should you
do next?
Discussion:
During the initial infection with TB, the bacilli
replicate in the alveoli, enter the lymphatics
and bloodstream, and disseminate through-
out the body.  For most people, the immune
system contains the infection through the for-
mation of granulomas.  Only about 5-10% of
persons infected will progress to active TB
during their lifetime with 80 - 85% of these
patients having pulmonary TB and 15 - 20%
having extrapulmonary TB.3
The most common extrapulmonary sites in
descending order of frequency are lymphatic,
pleural, bone and joint, meningeal, peri-
toneal, genitourinary, and then other sites.3
The presenting signs and symptoms depend
on the location of disease but may include
more typical symptoms such as fever, night
sweats, and weight loss.  Importantly, some
patients presenting with extrapulmonary
symptoms will have active pulmonary TB as
well.  The occurrence of active disease at
multiple sites is more common in immuno-
compromised patients, particularly those with
advanced HIV infection.  All patients being
evaluated for extrapulmonary TB should
have a chest radiograph due to the risk for
occult pulmonary TB with the potential for air-
borne transmission to others.
While diagnosing pulmonary TB can be chal-
lenging (Case 1), diagnosing extrapulmonary
disease can be even more difficult.  As with
pulmonary TB, the key to a timely diagnosis
requires consideration of TB in the differential
diagnosis. Many sites, like pleural, peritoneal,
meningeal, and pericardial, are associated
with a very low organism burden.  Therefore,
smears are rarely positive and cultures of
fluid are less than 50% sensitive.  Nucleic
acid amplification tests were developed in
part to address this limitation and are highly
specific but unfortunately lack sufficient sen-
sitivity to assume a negative test excludes
the diagnosis. 7 Therefore, definitive diagno-
sis of extrapulmonary TB often requires a tis-
sue sample for pathology and culture.
Delays in diagnosis of pulmonary and extra-
pulmonary TB can be increased by the empir-
ic use of fluoroquinolones.  Many fluoro-
quinolones are active against Mycobacterium
tuberculosis and some are under investiga-
tion as first line agents in combination thera-
py. 8,9  Because patients can have a profound
clinical response, clinicians may be fooled
into a false sense of security since treatment
with fluoroquinolones can temporarily lead to
suppression of organism growth in cultures.
As with any other single agent, treatment with
a fluoroquinolone will not cure TB, and
patients will relapse, often soon after stopping
therapy.
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In our patient, a biliary drain was placed for
symptom relief and plans made for surgical
exploration.  Prior to surgery, samples of his
biliary fluid and stool were sent to microbiolo-
gy, where an AFB smear was positive, and
eventually grew M. tuberculosis.  His clinical
response during the first hospitalization was
thought to be from the levofloxacin he
received, but his symptoms quickly returned
when he was switched to an antibiotic without
activity against M. tuberculosis.  He was start-
ed on standard four drug TB therapy with iso-
niazid, rifampin, pyrazinamide, and ethambu-
tol.  An HIV test was performed and was posi-
tive. The patient's CD4 cell count was
237/mm3 and it was decided to defer initiation
of HIV therapy for approximately three to six
months when there may be reduced risk of
immune reconstitution reaction.  When con-
comitantly administered, HIV and anti-tubercu-
lous therapy have to be carefully selected to
avoid drug-drug interactions (see IDCR
February 2006 and this issue's TB 101 for a
detailed discussion of antiretroviral and TB
drug interactions).
Rifamycin Dosing in TB/HIV Co-infection Non-Nucleoside Reverse Transcriptase Inhibitors
TB101: RIFAMYCIN DOSING IN TB/HIV CO-INFECTION
Consider increasing EFV to 800 mg QHS
No change necessary for Rifampin
Levels: EFV decreased by 25%
Efavirenz 
(EFV)
Contraindicated
Levels: DLV decreased by 95%
Delavirdine 
(DLV)
Not recommended
Levels: NVP decreased by 37-58%
Note: If alternative therapy not available, administer
standard doses of NVP and Rifampin and monitor
antiviral response and liver function tests closely as
combination may increase risk of hepatotoxicity
Increase Rifabutin to 450 mg daily
No dosing change necessary for EFV
Levels: Rifabutin decreased by 35%
Contraindicated 
Levels: DLV decreased by 80%
No dosing change necessary for Rifabutin or NVP
Levels: NVP decreased by 16%
Nevirapine 
(NVP)
Rifampin
Rifabutin
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If NOT RTV
boosted:
Decrease
Rifabutin to 150
mg daily or 300
mg 3x/week; 
Increase IDV to
1000 mg every
8 hours
Levels:
Rifabutin
increased by 2-
fold
IDV decrease by
32%
If RTV boosted:
Decrease
Rifabutin 150
mg QOD or 150
mg 3x/week; No
IDV dose adjust-
ments are nec-
essary
Levels:
No Data
Decrease
rifabutin to 150
mg QOD or
dose 3x/week. 
Levels:
Rifabutin con-
centrations
increase 4-fold.  
If NOT boosted:
Contraindicated
If RTV boosted:
Decrease
Rifabutin 150
mg QOD or 150
mg 3x/week.
No SQV dose
adjustments are
necessary
Levels:
No Data
With NFV 1250
mg Q12H
decrease
Rifabutin to 150
mg QD or 300
mg 3x/week. 
No NFV dose
adjustments are
necessary
Levels:
No Data
If RTV NOT
concomitantly
administered:
Decrease
Rifabutin to 150
mg QD or 300
mg 3x/week. 
No f-APV dose
adjustments are
necessary
Levels:
Rifabutin
increased 1.9-
fold  
If RTV boosted:
Decrease
Rifabutin to 150
mg QOD or
3x/week.  
Levels: Rifabutin
increased
Decrease
Rifabutin dose
to 150 mg QOD
or 3x/week
No ATV dose
adjustments are
necessary
Levels: Rifabutin
increased 2.5-
fold
Decrease
Rifabutin dose
to 150 mg QOD
or 3x/week. 
No dose adjust-
ments are nec-
essary for LPV/r
Levels: Rifabutin
increased 3-fold. 
Decrease
Rifabutin to 150
mg QOD or
3x/week.  
Levels: Rifabutin
increased 2.9-
fold.  
Indinavir
(IDV)
Ritonavir
Full dose
(RTV)
Saquinavir
(SQV)
Nelfinavir
(NFV)
Fosamprenavir
(f-APV)
Atazanavir
(ATV)
Lopinavir*
(LPV)
Tipranavir*
(TPV)
Rifabutin
Contraindicated
Levels:
IDV (unboosted)
decreased 89%
IDV (boosted)
decreased 87%
Alternate antimi-
crobial should
be considered.  
Levels:
RTV decreased
by 35%.
.  
Contraindicated
Levels:
SQV levels
decreased by
84%.
Note: Severe
hepatotoxicity
observed with
Saquinavir 1000
mg/RTV 100 mg
Q12 hours +
Rifampin 600
mg daily
Contraindicated
Levels: 
NFV decreased
by 82%
Contraindicated
Levels: 
APV decreased
by 82%; 
Contraindicated
Levels:
No data
Contraindicated
Levels: 
LPV decreased
by75%
Limited clinical
experience sug-
gests LPV/r 3
SGC + RTV 300
mg BID may
overcome inter-
action.
Hepatotoxicity
may be associ-
ated with
increase RTV
dose.  Rifabutin
is recommended
instead of
Rifampin
No data
Should NOT be
co-administered
Rifampin
By: Todd Correll. PharmD, BCPS and  Nichole Kiziah**, PharmD
Disclosures: TC: Consultant: Pfizer, Speaker's Bureau: Gilead Sciences, Abbott Laboratories;  NK: Speaker's Bureau:  Gilead, Boehringer-Ingelheim
NK: Assumes ATV, LPV and TPV boosted with RTV
Notes:
NRTIs not expected to have clinically significant interactions with rifamycins.  For patients with CD4 cell counts <100 cells/mm3, daily or three times
weekly TB regimens are preferred.  If patients are not receiving NNRTI- or PI-based antiretroviral therapy, Rifampin can be used in place of Rifabutin.
If a three times weekly TB regimen is preferred, Rifabutin does not require dose alteration when concomitantly administered with a RTV boosted PI-
based antiretroviral regimen (i.e. if on ATZ/RTV the Rifabutin dose would be 150 mg every other day or three times per week). Please see recommen-
dation in above table for Rifabutin dosing recommendations when co-administered with a PI.  
If an Efavirenz-based regimen is used, Rifabutin 600 mg three times weekly is recommended.  
INH, PZA and EMB require escalation in doses if a three times weekly regimen is preferred.
Rifamycin Dosing in TB/HIV Co-infection Protease Inhibitors
TB101: RIFAMYCIN DOSING IN TB/HIV CO-INFECTION (CONT.)
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Figure 1 - TB Screening: Minimal Risk Facility
Figure 2 - > TB Screening: Minimal Risk Facility
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Figure 3 - TB Screening: Minimal Risk Facility (No previous TST+ documented)
Source: Prevention and Control of Tuberculosis in Correctional and Detention Facilities: Recommendations from CDC. MMWR 2006;55(RR-9)
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Pattern of US Tuberculosis Cases Shifting
Utilizing data from a recent study of tuberculosis
(TB) cases among foreign-born persons in the
United States, this news article, published in the
Journal of the American Medical Association, high-
lights the changing epidemiological trends in tuber-
culosis (TB) cases in the United States.1 Despite
the fact that TB cases among US-born residents
between 1993 and 2004 fell by 62%, cases among
foreign-born residents rose by 5% during the same
time period, growing from 29% to 54% of total
cases.  Notably, of all the reported cases among for-
eign-born residents in 2004, about half had lived in
the United States for at least five years.  The
increasing proportion of cases among foreign-born
individuals who have lived in the United States for
more than five years renders existing recommenda-
tions, which call for tuberculin skin testing and treat-
ment of latent infections only among those who
have lived in the United States for less than five
years, obsolete.  While new guidelines are under
review, many experts, the article suggests, fear that
rising cases in immigrant populations together with
cutbacks in state and federal TB-control programs
could create a resurgence in TB cases, similar to
that seen in the United States in the late 1980s and
early 1990s.
1.Tuberculosis among foreign-born persons in the
United States: achieving tuberculosis elimination.
Cain, KP et al. American Journal of Respiratory
Critical Care Medicine. 2007; 175:75-79.    
Pattern of US Tuberculosis Cases Shifting.  Voelker,
R.  Journal of the American Medical Association.
2007 Feb;297(7): 685.
Missed Opportunities for Earlier Diagnosis of
HIV Infection - South Carolina, 1997-2005
In this study, originally published in MMWR, investi-
gators examined opportunities to detect HIV infec-
tion among all cases of HIV and AIDS reported in
South Carolina prior to the 2006 release of revised
CDC guidelines for HIV testing in health-care set-
tings.  Of the 4,315 reported cases of HIV infection
from 2001-2005, 41% were late-testers, defined as
persons in whom AIDS was diagnosed within one
year of the initial HIV diagnosis.  By linking data
from the South Carolina HIV/AIDS Reporting
System (HARS) and the South Carolina Office of
Research and Statistics (ORS), the investigators
were able to determine that 73% of the late-testers
had made at least one documented visit to a South
Carolina health-care facility between 1997 and
2005.  In total, these late-testers made 7,988 visits
to various facilities such as emergency departments
(79.9%), inpatient settings (12.3%), outpatient facil-
ities (7.4%), and free clinics (1.4%).  79% of the
resulting diagnoses were categorized as not likely
to be suggestive of an HIV infection, even though
33.9% of the late-testers were identified as persons
with high risk practices that should have prompted
HIV screening if risk histories had been elicited.
These findings, the authors assert, suggest that
routine, opt-out HIV screening of all patients, rather
than risk based testing, might result in substantially
earlier HIV diagnoses in South Carolina.
In an accompanying editorial, authors from the CDC
note that the findings from the South Carolina study
support the new recommendations for routine, opt-
out HIV screening in all health care settings.
Additionally, they highlight the fact that a substantial
proportion of the newly diagnosed HIV cases in
2004-2005 had low CD4+ cell counts, suggesting a
high prevalence and long duration of undiagnosed
HIV infections in South Carolina.  In considering the
limitations of the report, the members of the CDC
point out that certain HIV/AIDS diagnoses may not
have been reported to HARS/ORS, the matching of
records might not have been successful in all
cases, patients might have rejected HIV testing, and
certain late-testers may not have been HIV infected
during the time of their health care visits.  In conclu-
sion, they remark that the capacity of treatment and
preventive services in South Carolina will need to
increase if HIV testing is made routine. 
Missed Opportunities for Earlier Diagnosis of HIV
Infection - South Carolina, 1997-2005.  Duffus W. et
al.  Journal of the American Medical Association.
2007;297(2):149-150.
Reducing Tuberculosis Incidence by Tuberculin
Skin Testing, Preventive Treatment, and
Antiretroviral Therapy in an Area of Low
Tuberculosis Transmission
Researchers in Switzerland, an area with low rates
of TB transmission, assessed the effect of tuber-
culin skin testing (TST) and preventive treatment on
the incidence of tuberculosis (TB).  Using data from
the more than six thousand participants in the Swiss
HIV Cohort Study (SHCS), the investigators calcu-
lated a TB incidence of 0.22 cases per 100 person-
years in the overall study population.  Among the
69% of individuals who received TST, 9.4% had
positive results.  Significantly, if preventive treat-
ment was not administered, the incidence of TB was
found to be 1.6 cases per 100 person-years in those
patients with positive TST results.  In contrast, none
of the 193 TST positive patients who received pre-
ventive treatment developed TB.  Increased risk for
TB in the study population included: positive TST
results, missing TST results, origin from sub-
Saharan Africa, low CD4+ cell counts, and high
plasma HIV RNA levels.  Those patients receiving
combination antiretroviral therapy were at a
reduced risk.  The authors suggest that potential
study limitations include an underestimation of TB
incidence due to the short follow-up period of two
years and possible delay between the diagnosis of
HIV or TB and registration in SHCS.  Nonetheless,
the investigators conclude that screening for latent
TB using TST and preventive treatment for patients
with positive TST results remains an efficacious
strategy for reducing TB-associated morbidity in a
country with low rates of TB transmission.         
Reducing Tuberculosis Incidence by Tuberculin
Skin Testing, Preventive Treatment, and
Antiretroviral Therapy in an Area of Low
Tuberculosis Transmission.  Elzi, L et al.  Clinical
Infectious Diseases.  2007 Feb;44: 94-102.
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SELF-ASSESSMENT TEST FOR CONTINUING MEDICAL EDUCATION CREDIT
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for continuing
Medical Education through the joint sponsorship of Medical Education Collaborative, Inc. (MEC) and IDCR.  MEC is accredited by the ACCME to
provide continuing medical education for physicians. 
Medical Education Collaborative designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™.  Physicians should only
claim credit commensurate with the extent of their participation in the activity.  Statements of credit will be mailed within 6 to 8 weeks following the
program. 
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1. True or False? DOT should be used for the treatment of TB 
disease, intermittent treatment regimens for LTBI, and daily dosing 
treatment regimen of LTBI?
TRUE or FALSE?
2. Which of the following is NOT a factor that contributes to the high 
rate of TB infection in correction and detention facilities? 
A. The movement of inmates (without their medical records) from
institution to institution. 
B. The concentration of individuals at high risk for TB (e.g., users
of injected drugs, persons of low socio- economic status, and 
persons with HIV infection).  
C. The physical structure of correctional facilities that are in 
many cases overcrowded. 
D. All of the above
3. True or False? Two-step testing should be used for periodic testing
unless there is a lapse of greater than 12 months between periodic
tests and should be used in the context of a contact investigation. 
TRUE or FALSE?
4. All are limitations of QuantiFERON®-TB Gold. (QFT-G) EXCEPT:
A. Only a limited number of laboratories process the test. 
B. Blood specimen must be collected and processed within 12 
hours of collection. 
C. The rate of false positives in non-immnosuprressed patients. 
D. There is a lack of clinical experience in interpreting test 
results. 
5. Which of the following is not a factor that should prompt TB 
screening:
A. History of tobacco use 
B. Chronic renal failure
C. Hematologic malignancy or lymphoma
D. Immunosuppressive therapy
6. Which of the following statements regarding sputum smears is 
correct:
A. They have a poor sensitivity with only 50% of patients with 
active pulmonary TB having a positive smear
B. Patients who have smear negative disease can also transmit 
the infection
C. A single negative smear is sufficient to rule out  active disease
D. A and B
E. A, B and C
In order to receive credit, participants must score at least a 70% on the post test and submit it along with the credit 
application and evaluation form to the address/fax number indicated.  Statements of credit will be mailed within 6-8 weeks
following the program.
Please print clearly as illegible applications will result in a delay.
Name: _________________________________________________  Profession: __________________________________
License #: ___________________________________  State of License: __________________________________________
Address: ____________________________________________________________________________________________
City: ________________________ State: ________ Zip: ________________________ Telephone: ___________________
Please check which credit you are requesting  ___ ACCME   or    ___ Non Physicians
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
I certify that I participated in IDCR monograph - May 2007 Issue     
Please fill in the number of actual hours that you attended this activity.
Date of participation: ______________________  
Number of Hours (max. 1.5): ___________________
Signature: _________________________________________________
Please Submit Completed Application to:
Medical Education Collaborative
651 Corporate Circle, Suite 104, Golden CO 80401
Phone: 303-420-3252 FAX: 303-420-3259
For questions regarding the accreditation of this activity, please call
303-420-3252
Instructions:
• Applications for credit will be accepted until 
May 31, 2008.
• Late applications will not be accepted.
• Please anticipate 6-8 weeks to recieve your certificate.
Objectives:
The learner will be able to describe the appropriate usages of DOT when treating TB. 
The learner will be able to describe the factors that contribute to the high rates of TB infection in correctional facilities. 
The learner will become familiar with the recommended TB screening methods and procedures. 
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COURSE EVALUATION
I. Please evaluate this educational activity by checking the appropriate box:
Activity Evaluation
Faculty
Content
How well did this activity avoid com-
mercial bias and present content that
was fair and balanced?
What is the likelihood you will
change the way you practice based
on what you learned in this activity?
Overall, how would you rate 
this activity?
Excellent Very Good Good Fair Poor
II. Course Objectives 
Were the following overall course objectives met?  At the conclusion of this presentation, are you able to:
• The learner will be able to describe the appropriate usages of DOT when treating TB. YES NO SOMEWHAT
• The learner will be able to describe the factors that contribute to the high rates of TB infection YES NO SOMEWHAT
in correctional facilities.       
• The learner will become familiar with the recommended TB screening methods and procedures. YES NO SOMEWHAT
III. Additional Questions
a. Suggested topics and/or speakers you would like for future activities.
b.  Additional Comments 
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